Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis

Tools

Item Type:	Letter
Title:	Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis
Creators Name:	Albach, F.N., Minopoulou, I., Wilhelm, A., Biesen, R., Kleyer, A., Wiebe, E., Fleischmann, A., Frick, M., Damm, F., Gogolok, J., Serve, S., Locher, B.N., Borie, D., Casteleyn, V., Siegert, E., Dörner, T., Alexander, T., Furth, C., Zernicke, J., Movassaghi, K., Hütter-Krönke, M.L., Schrezenmeier, E., Schneider, U., Bullinger, L., Krönke, G., Penack, O. and Simon, D.
Abstract:	RHEUMATOLOGY KEY MESSAGE: Anti-CD19 CAR T-cell therapy might represent a therapeutic option for severe SSc and concomitant RA.
Source:	Rheumatology
ISSN:	1462-0324
Publisher:	Oxford University Press / British Society for Rheumatology
Volume:	64
Number:	6
Page Range:	4075-4077
Date:	June 2025
Official Publication:	https://doi.org/10.1093/rheumatology/keaf077
PubMed:	View item in PubMed

Repository Staff Only: item control page